Part 4/9:
Adding to the excitement, the potential market for Epidiolex is substantial. While initially addressing around 20,000 children, the broader landscape of epilepsy treatment in the U.S. involves approximately 2.4 million affected individuals. With peak sales estimates reaching as high as half a billion dollars, the economic prospects for Epidiolex are promising, assuming it gains FDA approval by June 27.